Dendrimers are polyfunctional nano-objects of perfectly defined structure that can provide innovative alternatives for the treatment of chronic inflammatory diseases, including multiple sclerosis (MS). To investigate the efficiency of a recently described amino-bis(methylene phosphonate)capped ABP dendrimer as a potential drug candidate for MS, we used the classical mouse model of MOG(35-55)-induced experimental autoimmune encephalomyelitis (EAR). Our study provides evidence that the ABP dendrirner prevents the development of EAR and inhibits the progression of established disease with a comparable therapeutic benefit as the approved treatment Fingolimod. We also show that the ABP dendrimer redirects the pathogenic myelin-specific CD4(+) T cell response toward IL-10 production.